SAGE Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 86   

Articles published

SAGE 167.34 +11.07 (7.08%)
price chart
A New Kind of Stock Chart: Sage Therapeutics Inc (NASDAQ:SAGE) Critical Pivot ...
This is a real time view of the critical technical pivot points for Sage Therapeutics Inc (NASDAQ:SAGE) . The technical pivot points we look at all surround the stock price movement from the last 10-trading days through the last year.
SAGE Therapeutics Inc. (SAGE) Is Soaring To A New High On Study Results
SAGE Therapeutics Inc. (SAGE) Is Soaring To A New High On Study Results. December 07, 2017, 09:33:00 AM EDT By RTT News. loading.
Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers  TheStreet.com
Sage Therapeutics Inc. (SAGE) Moves Higher on Volume Spike for December 08  Equities.com
UPDATE: Sage Therapeutics shares soar more than 74% on positive trial of ...
Sage Therapeutics Inc. shares SAGE, +7.08% soared more than 74% in premarket trade Thursday, after the company reported positive results in a midstage trial of a depression treatment.
Why Marinus Pharmaceuticals Shares Spiked On Sage Therapeutics News
Marinus Pharmaceuticals Inc (NASDAQ: MRNS) closed up 39.6 percent Thursday and continued another 3.9 percent pre-market Friday - but not on its own merits.
Here's Why Marinus Pharmaceuticals Rose as Much as 41.1% Thursday  Nasdaq
What's Propelling Marinus Pharmaceuticals, Inc. (MRNS) to Decline So Much?  WeeklyHub
SAGE Therapeutics Inc (NASDAQ:SAGE) Bullish Trend
A big black candle occurred. This is bearish, as prices closed significantly lower than they opened. If the candle appears when prices are “high,” it may be the first sign of a top.
Why Biotech Sage Therapeutics Is Overvalued
shares rocketed higher after the biopharmaceutical company reported positive phase 3 clinical results for its Brexanolone drug to treat postpartum depression.
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on December 1, 2017, the ...
Royal Bank Of Canada Cuts Sage Therapeutics (SAGE) Price Target to $137.00
Sage Therapeutics, Inc. logo Sage Therapeutics (NASDAQ:SAGE) had its target price lowered by Royal Bank Of Canada from $145.00 to $137.00 in a report issued on Monday, November 27th, The Fly reports.
Sage Therapeutics Inc. (SAGE) Breaks into New 52-Week High on December 08 ...  Equities.com
Amundi Pioneer Asset Management Inc. Purchases 22710 Shares of Sage ...  StockNewsTimes
Sage Therapeutics Inc. (SAGE) Breaks into New 52-Week High on November 24 Session
Shares of Sage Therapeutics Inc. (SAGE) broke into a new 52-week high yesterday, hitting a peak of $100.34. Shares closed at $97.71 after opening at $95.67 for a move of 2.38%.
What Recent Ownership Trends Suggest About Sage Therapeutics, Inc. (SAGE ...  StockNewsGazette
Candriam Luxembourg SCA Has $3.36 Million Position in Sage Therapeutics, Inc ...  The Ledger Gazette
Entellus Medical, Inc. (ENTL) is better stock pick than Sage Therapeutics, Inc ...
The shares of Entellus Medical, Inc. have increased by more than 26.46% this year alone. The shares recently went up by 49.84% or $7.98 and now trades at $23.99.
Analyst's Viewpoint About Sage Therapeutics, Inc. (SAGE), Entellus ...  USA Commerce Daily
32 Biggest Movers From Yesterday  Benzinga